Publication of Prospectus

Regulatory News Service

22 June 2018 07:00 BST

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:

Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

The last drawdown under the EMTN programme was in 2016.

To view the full document, please paste the following URL into the address bar of your browser.

https://www.astrazeneca.com/content/dam/az/media-centre-docs/press-releases/2018/AstraZeneca%20PLC%20EMTN%20Update%202018%20-%20Base%20Prospectus%20226679-3-39%20v0.1.pdf

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

http://www.morningstar.co.uk/uk/NSM

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 


CONTACTS

     

Media Relations

 

 

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

     

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Josie Afolabi

 

+44 203 749 5631

Craig Marks

Finance; Fixed Income; M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free

 

+1 866 381 7277

 

 

 

Adrian Kemp
Company Secretary
AstraZeneca PLC
 

tags

  • Regulatory